Jamie W. Robinson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jamie W. Robinson has a total of 206 co-authors. Here are the top co-authors by number of shared publications:
- Gibran Hemani
University of Bristol
6 shared publications - Jie Zheng
University of Bristol
6 shared publications - Kathreena M. Kurian
Brain Tumour Research Centre, Bristol Medical School, University of Bristol , Bristol
5 shared publications Jie Zheng
University of Bristol
4 shared publications- Christina Dardani
University of Bristol
3 shared publications George Davey Smith
Medical Research Council Integrative Epidemiology Unit, Bristol Medical School, University of Bristol
3 shared publications
Latest Publications
- 10 September 2026
- Published by Elsevier in Neuropharmacology
- Vol. 301
Glycine transporter 1 inhibitor, bitopertin, changes excitatory and inhibitory network connectivity in mouse medial prefrontal cortex
- 10 September 2026
- Published by Elsevier in Neuropharmacology
- Vol. 301
Glycine transporter 1 inhibitor, bitopertin, changes excitatory and inhibitory network connectivity in mouse medial prefrontal cortex
- Open Access
Revisiting the Links Between Asthma and the Psychosis Spectrum: shared molecular mechanisms
Epidemiological studies suggest associations of asthma with the psychosis spectrum (psychotic experiences, bipolar disorder, schizophrenia), but the mechanisms underlying these associations remain unclear. We examined the relationship between asthma and psychosis-related outcomes using observational cohort, polygenic score, and Mendelian randomization (MR) analyses, and assessed the possibility of shared genetic underpinnings between these traits using genetic colocalisation. Results from a UK population-based prospective birth cohort suggest that asthma at age 7 and polygenic risk for asthma are associated with psychotic experiences in early adulthood. Results from two-sample MR analyses do not support causal relationships of genetic liability to asthma with bipolar disorder or schizophrenia. Instead, genetic correlation and colocalization analyses point to the presence of shared genetic aetiology between the conditions. We identified 8 genomic regions with potentially shared causal genes between asthma and bipolar disorder or asthma and schizophrenia. Using genetically predicted mRNA expression in condition-relevant tissues (brain and lung), we identified 16 genes shared between conditions, which include FADS1 , SLC4A10, BDH2, and CISD2 . Our results suggest that population-level associations of asthma with psychosis spectrum conditions could be due to shared molecular mechanisms involving fatty acid metabolism, ion channel activity, and iron homeostasis.
Open AccessRevisiting the Links Between Asthma and the Psychosis Spectrum: shared molecular mechanisms
Epidemiological studies suggest associations of asthma with the psychosis spectrum (psychotic experiences, bipolar disorder, schizophrenia), but the mechanisms underlying these associations remain unclear. We examined the relationship between asthma and psychosis-related outcomes using observational cohort, polygenic score, and Mendelian randomization (MR) analyses, and assessed the possibility of shared genetic underpinnings between these traits using genetic colocalisation. Results from a UK population-based prospective birth cohort suggest that asthma at age 7 and polygenic risk for asthma are associated with psychotic experiences in early adulthood. Results from two-sample MR analyses do not support causal relationships of genetic liability to asthma with bipolar disorder or schizophrenia. Instead, genetic correlation and colocalization analyses point to the presence of shared genetic aetiology between the conditions. We identified 8 genomic regions with potentially shared causal genes between asthma and bipolar disorder or asthma and schizophrenia. Using genetically predicted mRNA expression in condition-relevant tissues (brain and lung), we identified 16 genes shared between conditions, which include FADS1 , SLC4A10, BDH2, and CISD2 . Our results suggest that population-level associations of asthma with psychosis spectrum conditions could be due to shared molecular mechanisms involving fatty acid metabolism, ion channel activity, and iron homeostasis.
- Open Access
- 20 November 2024
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 34 (2) , 178-192
Brain multi-omic Mendelian randomisation to identify novel drug targets for gliomagenesis
Genetic variants associated with molecular traits that are also associated with liability to glioma can provide causal evidence for the identification and prioritisation of drug targets. We performed comprehensive two-sample Mendelian randomisation (Wald ratio and/or IVW) and colocalisation analyses of molecular traits on glioma. Instrumentable traits (QTLs P < 5 × 10−8) were identified amongst 11 985 gene expression measures, 13 285 splicing isoforms and 10 198 protein abundance measures, derived from 15 brain regions. Glioma summary-level data was extracted from a genome-wide association meta-analysis of 12 496 cases and 18 190 controls. We found evidence for causal effect of 22 molecular traits (across 18 genes/proteins) on glioma risk. Thirteen molecular traits have been previously linked with glioma risk and five were novel; HBEGF (5q31.3) expression and all glioma [OR 1.36 (95%CI 1.19–1.55); P = 4.41 × 10−6]; a CEP192 (18p11.21) splice isoform and glioblastoma [OR 4.40 (95%CI 2.28–8.48); P = 9.78 × 10−4]; a FAIM (3q22.3) splice isoform and all glioma [OR 2.72–3.43; P = 1.03 × 10−5 to 1.09 × 10−5]; a SLC8A1 (2p22.1) splice isoform and all glioma [OR 0.37 (95%CI 0.24–0.56; P = 5.72 × 10−6]; D2HGDH (2q37.3) protein and all glioma [OR 0.86 (95%CI 0.80–0.92); P = 5.94 × 10−6)]. We provide robust causal evidence for prioritising genes and their protein products in glioma research. Our results highlight the importance of alternative splicing as a mechanism in gliomagenesis and as an avenue for exploration of drug targets.
- 20 November 2024
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 34 (2) , 178-192
Open AccessBrain multi-omic Mendelian randomisation to identify novel drug targets for gliomagenesis
Genetic variants associated with molecular traits that are also associated with liability to glioma can provide causal evidence for the identification and prioritisation of drug targets. We performed comprehensive two-sample Mendelian randomisation (Wald ratio and/or IVW) and colocalisation analyses of molecular traits on glioma. Instrumentable traits (QTLs P < 5 × 10−8) were identified amongst 11 985 gene expression measures, 13 285 splicing isoforms and 10 198 protein abundance measures, derived from 15 brain regions. Glioma summary-level data was extracted from a genome-wide association meta-analysis of 12 496 cases and 18 190 controls. We found evidence for causal effect of 22 molecular traits (across 18 genes/proteins) on glioma risk. Thirteen molecular traits have been previously linked with glioma risk and five were novel; HBEGF (5q31.3) expression and all glioma [OR 1.36 (95%CI 1.19–1.55); P = 4.41 × 10−6]; a CEP192 (18p11.21) splice isoform and glioblastoma [OR 4.40 (95%CI 2.28–8.48); P = 9.78 × 10−4]; a FAIM (3q22.3) splice isoform and all glioma [OR 2.72–3.43; P = 1.03 × 10−5 to 1.09 × 10−5]; a SLC8A1 (2p22.1) splice isoform and all glioma [OR 0.37 (95%CI 0.24–0.56; P = 5.72 × 10−6]; D2HGDH (2q37.3) protein and all glioma [OR 0.86 (95%CI 0.80–0.92); P = 5.94 × 10−6)]. We provide robust causal evidence for prioritising genes and their protein products in glioma research. Our results highlight the importance of alternative splicing as a mechanism in gliomagenesis and as an avenue for exploration of drug targets.
- Open Access
Reverse Mendelian randomization separates causes from early proteomic biomarkers of glioma
Background/Objectives: Glioma represents the largest entity of primary brain tumours in adults, with an overall survival of less than 20% over 5 years. Glioblastoma is the most frequent and aggressive glioma subtype. At present, there are few well-established pre-clinical predictors for glioma incidence. Due to the availability and size of prognostic studies in glioma, we utilised a Mendelian randomization framework to identify non-causal protein biomarkers which are associated with early-onset of glioma in the European population. Methods: We generated polygenic risk scores (PRS) for glioma (n=12,496), glioblastoma (n=6,191), and non-glioblastoma (n=5,819) cases. We used reverse Mendelian randomization (MR) to examine the relationship between the genetic liability of glioma and 1,463 and 90 proteins were measured using an Olink panel (UKBB, n=35,571 and SCALLOP, n=21,758), additionally 4,907 and 2,994 aptamers were assayed using SOMAscan assays (deCODE n=35,559 and INTERVAL, n=3,301). We further performed a forward cis-MR and colocalization analysis leveraging the circulating protein markers in risk of glioma, glioblastoma and non-glioblastoma. Results: Reverse MR identified 161 unique proteins associated with the PRS of glioma, 79 proteins associated with the PRS of glioblastoma, and 11 proteins associated with the PRS of non-glioblastoma. Enrichment analyses identified a proportion of plasma proteins to be associated with the PRS of glioma to be correlated with response to external stimulus. A group of plasma proteins linked to the PRS of glioma and glioblastoma were related to the immune system process. Forward MR of the putative relationships were found to have little or no evidence of association on the causal pathway. Candidate markers ETFA, RIR1 and BT3A1 are evidenced in glioma risk. Conclusion: Our findings identify a high genetic liability to glioma is associated with the immune system processes. Non-causal plasma biomarkers identified through PRS associations could indicate novel non-causal biomarkers of early glioma development.
Open AccessReverse Mendelian randomization separates causes from early proteomic biomarkers of glioma
Background/Objectives: Glioma represents the largest entity of primary brain tumours in adults, with an overall survival of less than 20% over 5 years. Glioblastoma is the most frequent and aggressive glioma subtype. At present, there are few well-established pre-clinical predictors for glioma incidence. Due to the availability and size of prognostic studies in glioma, we utilised a Mendelian randomization framework to identify non-causal protein biomarkers which are associated with early-onset of glioma in the European population. Methods: We generated polygenic risk scores (PRS) for glioma (n=12,496), glioblastoma (n=6,191), and non-glioblastoma (n=5,819) cases. We used reverse Mendelian randomization (MR) to examine the relationship between the genetic liability of glioma and 1,463 and 90 proteins were measured using an Olink panel (UKBB, n=35,571 and SCALLOP, n=21,758), additionally 4,907 and 2,994 aptamers were assayed using SOMAscan assays (deCODE n=35,559 and INTERVAL, n=3,301). We further performed a forward cis-MR and colocalization analysis leveraging the circulating protein markers in risk of glioma, glioblastoma and non-glioblastoma. Results: Reverse MR identified 161 unique proteins associated with the PRS of glioma, 79 proteins associated with the PRS of glioblastoma, and 11 proteins associated with the PRS of non-glioblastoma. Enrichment analyses identified a proportion of plasma proteins to be associated with the PRS of glioma to be correlated with response to external stimulus. A group of plasma proteins linked to the PRS of glioma and glioblastoma were related to the immune system process. Forward MR of the putative relationships were found to have little or no evidence of association on the causal pathway. Candidate markers ETFA, RIR1 and BT3A1 are evidenced in glioma risk. Conclusion: Our findings identify a high genetic liability to glioma is associated with the immune system processes. Non-causal plasma biomarkers identified through PRS associations could indicate novel non-causal biomarkers of early glioma development.
- Open Access
Immunological Drivers and Potential Novel Drug Targets for Major Psychiatric, Neurodevelopmental, and Neurodegenerative Conditions
Immune dysfunction is implicated in the aetiology of psychiatric, neurodevelopmental, and neurodegenerative conditions, but the issue of causality remains unclear, impeding attempts to develop new interventions. Using genomic data on protein and gene expression across blood and brain, we assessed evidence of a potential causal role for 736 immune response-related biomarkers on 7 neuropsychiatric conditions by applying Mendelian randomization (MR) and genetic colocalisation analyses. A systematic three-tier approach, grouping biomarkers based on increasingly stringent criteria, was used to appraise evidence of causality (passing MR sensitivity analyses, colocalisation, False Discovery Rate and Bonferroni thresholds). We provide evidence for a potential causal role of 29 biomarkers for 7 conditions. The identified biomarkers suggest a role of both brain specific and systemic immune response in the aetiology of schizophrenia, Alzheimers disease, depression, and bipolar disorder. Of the identified biomarkers, 20 appeared to be therapeutically tractable, including ACE , TNFRSF17 , SERPING1 , AGER and CD40, with drugs approved or in advanced clinical trials. Based on the largest available selection of plasma immune-response related biomarkers, our study provides insight into possible influential biomarkers for the aetiology of neuropsychiatric conditions. These genetically prioritised biomarkers now require further examination to evaluate causality, their role in the aetiological mechanisms underlying the conditions and therapeutic potential.
Open AccessImmunological Drivers and Potential Novel Drug Targets for Major Psychiatric, Neurodevelopmental, and Neurodegenerative Conditions
Immune dysfunction is implicated in the aetiology of psychiatric, neurodevelopmental, and neurodegenerative conditions, but the issue of causality remains unclear, impeding attempts to develop new interventions. Using genomic data on protein and gene expression across blood and brain, we assessed evidence of a potential causal role for 736 immune response-related biomarkers on 7 neuropsychiatric conditions by applying Mendelian randomization (MR) and genetic colocalisation analyses. A systematic three-tier approach, grouping biomarkers based on increasingly stringent criteria, was used to appraise evidence of causality (passing MR sensitivity analyses, colocalisation, False Discovery Rate and Bonferroni thresholds). We provide evidence for a potential causal role of 29 biomarkers for 7 conditions. The identified biomarkers suggest a role of both brain specific and systemic immune response in the aetiology of schizophrenia, Alzheimers disease, depression, and bipolar disorder. Of the identified biomarkers, 20 appeared to be therapeutically tractable, including ACE , TNFRSF17 , SERPING1 , AGER and CD40, with drugs approved or in advanced clinical trials. Based on the largest available selection of plasma immune-response related biomarkers, our study provides insight into possible influential biomarkers for the aetiology of neuropsychiatric conditions. These genetically prioritised biomarkers now require further examination to evaluate causality, their role in the aetiological mechanisms underlying the conditions and therapeutic potential.
- Open Access
Association between circulating inflammatory markers and adult cancer risk: a Mendelian randomization analysis
Background: Tumour-promoting inflammation is a “hallmark” of cancer and conventional epidemiological studies have reported links between various inflammatory markers and cancer risk. The causal nature of these relationships and, thus, the suitability of these markers as intervention targets for cancer prevention is unclear. Methods: We meta-analysed 6 genome-wide association studies of circulating inflammatory markers comprising 59,969 participants of European ancestry. We then used combined cis -Mendelian randomization and colocalisation analysis to evaluate the causal role of 66 circulating inflammatory markers in risk of 30 adult cancers in 338,162 cancer cases and up to 824,556 controls. Genetic instruments for inflammatory markers were constructed using genome-wide significant ( P < 5.0 x 10 -8 ) cis -acting SNPs (i.e. in or ±250 kb from the gene encoding the relevant protein) in weak linkage disequilibrium (LD, r 2 < 0.10). Effect estimates were generated using inverse-variance weighted random-effects models and standard errors were inflated to account for weak LD between variants with reference to the 1000 Genomes Phase 3 CEU panel. A false discovery rate (FDR)-corrected P -value (“ q -value”) < 0.05 was used as a threshold to define “strong evidence” to support associations and 0.05 ≤ q -value < 0.20 to define “suggestive evidence”. A colocalisation posterior probability (PPH 4 ) > 70% was employed to indicate support for shared causal variants across inflammatory markers and cancer outcomes. Results: We found strong evidence to support an association of genetically-proxied circulating pro-adrenomedullin concentrations with increased breast cancer risk (OR 1.19, 95% CI 1.10-1.29, q -value=0.033, PPH 4 =84.3%) and suggestive evidence to support associations of interleukin-23 receptor concentrations with increased pancreatic cancer risk (OR 1.42, 95% CI 1.20-1.69, q -value=0.055, PPH 4 =73.9%), prothrombin concentrations with decreased basal cell carcinoma risk (OR 0.66, 95% CI 0.53-0.81, q -value=0.067, PPH 4 =81.8%), macrophage migration inhibitory factor concentrations with increased bladder cancer risk (OR 1.14, 95% CI 1.05-1.23, q -value=0.072, PPH 4 =76.1%), and interleukin-1 receptor-like 1 concentrations with decreased triple-negative breast cancer risk (OR 0.92, 95% CI 0.88-0.97, q -value=0.15), PPH 4 =85.6%). For 22 of 30 cancer outcomes examined, there was little evidence ( q -value ≥ 0.20) that any of the 66 circulating inflammatory markers examined were associated with cancer risk. Conclusion: Our comprehensive joint Mendelian randomization and colocalisation analysis of the role of circulating inflammatory markers in cancer risk identified potential roles for 5 circulating inflammatory markers in risk of 5 site-specific cancers. Contrary to reports from some prior conventional epidemiological studies, we found little evidence of association of circulating inflammatory markers with the majority of site-specific cancers evaluated.
Open AccessAssociation between circulating inflammatory markers and adult cancer risk: a Mendelian randomization analysis
Background: Tumour-promoting inflammation is a “hallmark” of cancer and conventional epidemiological studies have reported links between various inflammatory markers and cancer risk. The causal nature of these relationships and, thus, the suitability of these markers as intervention targets for cancer prevention is unclear. Methods: We meta-analysed 6 genome-wide association studies of circulating inflammatory markers comprising 59,969 participants of European ancestry. We then used combined cis -Mendelian randomization and colocalisation analysis to evaluate the causal role of 66 circulating inflammatory markers in risk of 30 adult cancers in 338,162 cancer cases and up to 824,556 controls. Genetic instruments for inflammatory markers were constructed using genome-wide significant ( P < 5.0 x 10 -8 ) cis -acting SNPs (i.e. in or ±250 kb from the gene encoding the relevant protein) in weak linkage disequilibrium (LD, r 2 < 0.10). Effect estimates were generated using inverse-variance weighted random-effects models and standard errors were inflated to account for weak LD between variants with reference to the 1000 Genomes Phase 3 CEU panel. A false discovery rate (FDR)-corrected P -value (“ q -value”) < 0.05 was used as a threshold to define “strong evidence” to support associations and 0.05 ≤ q -value < 0.20 to define “suggestive evidence”. A colocalisation posterior probability (PPH 4 ) > 70% was employed to indicate support for shared causal variants across inflammatory markers and cancer outcomes. Results: We found strong evidence to support an association of genetically-proxied circulating pro-adrenomedullin concentrations with increased breast cancer risk (OR 1.19, 95% CI 1.10-1.29, q -value=0.033, PPH 4 =84.3%) and suggestive evidence to support associations of interleukin-23 receptor concentrations with increased pancreatic cancer risk (OR 1.42, 95% CI 1.20-1.69, q -value=0.055, PPH 4 =73.9%), prothrombin concentrations with decreased basal cell carcinoma risk (OR 0.66, 95% CI 0.53-0.81, q -value=0.067, PPH 4 =81.8%), macrophage migration inhibitory factor concentrations with increased bladder cancer risk (OR 1.14, 95% CI 1.05-1.23, q -value=0.072, PPH 4 =76.1%), and interleukin-1 receptor-like 1 concentrations with decreased triple-negative breast cancer risk (OR 0.92, 95% CI 0.88-0.97, q -value=0.15), PPH 4 =85.6%). For 22 of 30 cancer outcomes examined, there was little evidence ( q -value ≥ 0.20) that any of the 66 circulating inflammatory markers examined were associated with cancer risk. Conclusion: Our comprehensive joint Mendelian randomization and colocalisation analysis of the role of circulating inflammatory markers in cancer risk identified potential roles for 5 circulating inflammatory markers in risk of 5 site-specific cancers. Contrary to reports from some prior conventional epidemiological studies, we found little evidence of association of circulating inflammatory markers with the majority of site-specific cancers evaluated.
- Open Access
An efficient and robust tool for colocalisation: Pair-wise Conditional and Colocalisation (PWCoCo)
Genetic colocalisation is an important tool to test for shared genetic aetiology and is commonly used to strengthen causal inference in genetic studies of molecular traits and drug targets. However, the single causal variant assumption of the original colocalization method is a considerable limitation in genomic regions with multiple causal effects. We integrated conditional analyses (GCTA-COJO) and colocalisation analyses (coloc), into a novel analysis tool called Pair-Wise Conditional Colocalization (PWCoCo). PWCoCo performs conditional analyses to identify independent signals for the two tested traits in a genomic region and then conducts colocalisation of each pair of conditionally independent signals for the two traits using summary-level data. This allows for the stringent single-variant assumption to hold for each pair of colocalisation analysis. We found that the computational efficiency of PWCoCo is on average better than colocalisation with Sum of Single Effects Regression using Summary Stats (SuSiE-RSS), with greater gains in efficiency for high-throughput analysis. In a case study using GWAS data for multiple sclerosis and brain cortex-derived eQTLs (MetaBrain), we recapitulated all previously identified genes, which showcased the robustness of the method. We further found colocalisation evidence for secondary signals in nine additional loci, which was not identifiable in conventional GWAS and/or colocalisation. PWCoCo offers key improvements over existing methods, including: (1) robust colocalisation when the single variant assumption is violated; (2) independent colocalisation of secondary signals, which enables identification of novel disease-causing variants; (3) an easy-to-use and computationally efficient tool to test for colocalisation of high-dimensional omics data.
Open AccessAn efficient and robust tool for colocalisation: Pair-wise Conditional and Colocalisation (PWCoCo)
Genetic colocalisation is an important tool to test for shared genetic aetiology and is commonly used to strengthen causal inference in genetic studies of molecular traits and drug targets. However, the single causal variant assumption of the original colocalization method is a considerable limitation in genomic regions with multiple causal effects. We integrated conditional analyses (GCTA-COJO) and colocalisation analyses (coloc), into a novel analysis tool called Pair-Wise Conditional Colocalization (PWCoCo). PWCoCo performs conditional analyses to identify independent signals for the two tested traits in a genomic region and then conducts colocalisation of each pair of conditionally independent signals for the two traits using summary-level data. This allows for the stringent single-variant assumption to hold for each pair of colocalisation analysis. We found that the computational efficiency of PWCoCo is on average better than colocalisation with Sum of Single Effects Regression using Summary Stats (SuSiE-RSS), with greater gains in efficiency for high-throughput analysis. In a case study using GWAS data for multiple sclerosis and brain cortex-derived eQTLs (MetaBrain), we recapitulated all previously identified genes, which showcased the robustness of the method. We further found colocalisation evidence for secondary signals in nine additional loci, which was not identifiable in conventional GWAS and/or colocalisation. PWCoCo offers key improvements over existing methods, including: (1) robust colocalisation when the single variant assumption is violated; (2) independent colocalisation of secondary signals, which enables identification of novel disease-causing variants; (3) an easy-to-use and computationally efficient tool to test for colocalisation of high-dimensional omics data.
- Open Access
Genetic regulation of the human plasma proteome in 54,306 UK Biobank participants
The UK Biobank Pharma Proteomics Project (UKB-PPP) is a collaboration between the UK Biobank (UKB) and thirteen biopharmaceutical companies characterising the plasma proteomic profiles of 54,306 UKB participants. Here, we describe results from the first phase of UKB-PPP, including protein quantitative trait loci (pQTL) mapping of 1,463 proteins that identifies 10,248 primary genetic associations, of which 85% are newly discovered. We also identify independent secondary associations in 92% of cis and 29% of trans loci, expanding the catalogue of genetic instruments for downstream analyses. The study provides an updated characterisation of the genetic architecture of the plasma proteome, leveraging population-scale proteomics to provide novel, extensive insights into trans pQTLs across multiple biological domains. We highlight genetic influences on ligand-receptor interactions and pathway perturbations across a diverse collection of cytokines and complement proteins, and illustrate long-range epistatic effects of ABO blood group and FUT2 secretor status on proteins with gastrointestinal tissue-enriched expression. We demonstrate the utility of these data for drug target discovery by extending the genetic proxied effect of PCSK9 levels on lipid concentrations, cardio- and cerebro-vascular diseases, and additionally disentangle specific genes and proteins perturbed at COVID-19 susceptibility loci. This public-private partnership provides the scientific community with an open-access proteomics resource of unprecedented breadth and depth to help elucidate biological mechanisms underlying genetic discoveries and accelerate the development of novel biomarkers and therapeutics.
Open AccessGenetic regulation of the human plasma proteome in 54,306 UK Biobank participants
The UK Biobank Pharma Proteomics Project (UKB-PPP) is a collaboration between the UK Biobank (UKB) and thirteen biopharmaceutical companies characterising the plasma proteomic profiles of 54,306 UKB participants. Here, we describe results from the first phase of UKB-PPP, including protein quantitative trait loci (pQTL) mapping of 1,463 proteins that identifies 10,248 primary genetic associations, of which 85% are newly discovered. We also identify independent secondary associations in 92% of cis and 29% of trans loci, expanding the catalogue of genetic instruments for downstream analyses. The study provides an updated characterisation of the genetic architecture of the plasma proteome, leveraging population-scale proteomics to provide novel, extensive insights into trans pQTLs across multiple biological domains. We highlight genetic influences on ligand-receptor interactions and pathway perturbations across a diverse collection of cytokines and complement proteins, and illustrate long-range epistatic effects of ABO blood group and FUT2 secretor status on proteins with gastrointestinal tissue-enriched expression. We demonstrate the utility of these data for drug target discovery by extending the genetic proxied effect of PCSK9 levels on lipid concentrations, cardio- and cerebro-vascular diseases, and additionally disentangle specific genes and proteins perturbed at COVID-19 susceptibility loci. This public-private partnership provides the scientific community with an open-access proteomics resource of unprecedented breadth and depth to help elucidate biological mechanisms underlying genetic discoveries and accelerate the development of novel biomarkers and therapeutics.
- Open Access
Multi-omics Mendelian randomisation using expression, splicing and protein quantitative trait loci: identification of novel drug targets for gliomagenesis
Background: Genetic variants associated with molecular traits that are also associated with liability to glioma can provide causal evidence for the prioritisation of these traits as candidate drug targets. Methods: We performed two-sample Mendelian randomisation and genetic colocalisation of a large panel of molecular traits on glioma. Molecular data were taken from studies of expression quantitative trait loci (QTL) [11,985 genes]; splicing QTL [13,285 genes] and protein QTL [7,376 proteins] derived from 15 brain tissues. Glioma summary-level data was extracted from a genome-wide association meta-analysis of 12,496 cases and 18,190 controls. Results: Our MR analysis showed evidence for a causal effect of 85 molecular traits on glioma – 37 were robust according to colocalisation and Steiger filtering. We found causal evidence for 10 genes previously associated with glioma risk. We identified one novel genetic locus with strong causal evidence in the gene expression analysis: HBEGF (5q31.3) in all glioma [OR 1.36 (95%CI 1.19 to 1.55); P = 4.41 x 10 -6 ]. We also identified three novel genetic loci with strong causal evidence in the splicing variation analysis: CEP192 (18p11.21) in glioblastoma [OR 4.40 (95%CI 2.28 to 8.48); P = 9.78 x 10 -4 ]; FAIM (3q22.3) in all glioma [OR 2.72 to 3.43; P = 1.03 x 10 -5 to 1.09 x 10 -5 ] and SLC8A1 (2p22.1) in all glioma [OR 0.37 (95%CI 0.24 to 0.56; P = 5.72 x 10 -6 ]. Conclusions: We provide robust causal evidence for genes previously associated with glioma risk in genome-wide association studies, as well as four novel genes.
Open AccessMulti-omics Mendelian randomisation using expression, splicing and protein quantitative trait loci: identification of novel drug targets for gliomagenesis
Background: Genetic variants associated with molecular traits that are also associated with liability to glioma can provide causal evidence for the prioritisation of these traits as candidate drug targets. Methods: We performed two-sample Mendelian randomisation and genetic colocalisation of a large panel of molecular traits on glioma. Molecular data were taken from studies of expression quantitative trait loci (QTL) [11,985 genes]; splicing QTL [13,285 genes] and protein QTL [7,376 proteins] derived from 15 brain tissues. Glioma summary-level data was extracted from a genome-wide association meta-analysis of 12,496 cases and 18,190 controls. Results: Our MR analysis showed evidence for a causal effect of 85 molecular traits on glioma – 37 were robust according to colocalisation and Steiger filtering. We found causal evidence for 10 genes previously associated with glioma risk. We identified one novel genetic locus with strong causal evidence in the gene expression analysis: HBEGF (5q31.3) in all glioma [OR 1.36 (95%CI 1.19 to 1.55); P = 4.41 x 10 -6 ]. We also identified three novel genetic loci with strong causal evidence in the splicing variation analysis: CEP192 (18p11.21) in glioblastoma [OR 4.40 (95%CI 2.28 to 8.48); P = 9.78 x 10 -4 ]; FAIM (3q22.3) in all glioma [OR 2.72 to 3.43; P = 1.03 x 10 -5 to 1.09 x 10 -5 ] and SLC8A1 (2p22.1) in all glioma [OR 0.37 (95%CI 0.24 to 0.56; P = 5.72 x 10 -6 ]. Conclusions: We provide robust causal evidence for genes previously associated with glioma risk in genome-wide association studies, as well as four novel genes.
- Open Access
Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer’s disease risk in the general population: a Mendelian randomization study
Aims/hypothesis: Metformin use has been associated with reduced incident dementia in diabetic patients in observational studies. However, the causality between the two in the general population is unclear. This study uses Mendelian randomization (MR) to investigate the causal effect of metformin targets on Alzheimer’s disease (AD) and potential causal mechanisms in the brain linking the two. Methods: Genetic proxies for the effects of metformin drug targets were identified as variants in the gene for the corresponding target that associated with HbA 1c level (N=344,182) and expression level of the corresponding gene (N≤31,684). The cognitive outcomes were derived from genome-wide association studies comprising of 527,138 middle-aged Europeans, including 71,880 AD or AD-by-proxy patients. MR estimates representing lifelong metformin use on AD and cognitive function in the general population were generated. Effect of expression level of 22 metformin-related genes in brain cortex (N=6,601 donors) on AD was further estimated. Results: Genetically proxied metformin use equivalent to a 6.75 mmol/mol (1.09%) reduction of HbA 1c was associated with 4% lower odds of AD (odds ratio [OR]=0.964, 95%CI=0.982∼0.946, P=1.06×10 −4 ) in non-diabetic individuals. One metformin target, mitochondrial complex 1 (MCI), showed a robust effect on AD (OR=0.88, P=4.73×10 −4 ) that was independent of AMPK. MR of expression in brain cortex tissue showed that decreased MCI-related gene, NDUFA2 , expression was associated with reduced AD risk (OR=0.95, P=4.64×10 −4 ) and less cognitive decline. Conclusion/interpretation: Metformin use is likely to cause reduced AD risk in the general population. Mitochondrial function and the NDUFA2 gene are likely mechanisms of action in dementia protection. Research in context: What is already known about this subject: Metformin is an anti-diabetic drug with repurposing potential for dementia prevention. In a search of PubMed, Embase and clinicaltrials.gov , a few observational studies suggested the association of metformin use with reduced dementia incidence in diabetic patients What is the key question?: What is the effect of genetically proxied metformin use on Alzheimer’s disease (AD) and cognitive function in the general population, especially for those without diabetes? Is the causal role between the two at least partly influenced by mechanisms in the brain? What are the new findings?: In a Mendelian randomization analysis of over 527,138 individuals (71,880 AD or AD-by-proxy cases), genetically proxied metformin use equivalent to a 6.75 mmol/mol (1.09%) reduction of HbA 1c was associated with 14% lower odds of AD (odds ratio=0.86), where mitochondrial complex I is a key effect modifier. Expression level of a mitochondrial complex I related gene, NDUFA2 , showed an effect on reducing AD risk and less cognitive decline in brain. How might this impact on clinical practice in the foreseeable future?: Our study predicts the efficacy of metformin on reducing AD risk and reducing cognitive decline in the general population, especially for those without diabetes. Mitochondrial function and a mitochondrial related gene, NDUFA2 , could be considered as a novel drug target for dementia prevention. Graphical Tweet Effect of metformin targets reduced 4% of Alzheimer’s disease risk in non-diabetic individuals. @oldz84 @tomgaunt @mendel_random @mrc_ieu
Open AccessEvaluating the efficacy and mechanism of metformin targets on reducing Alzheimer’s disease risk in the general population: a Mendelian randomization study
Aims/hypothesis: Metformin use has been associated with reduced incident dementia in diabetic patients in observational studies. However, the causality between the two in the general population is unclear. This study uses Mendelian randomization (MR) to investigate the causal effect of metformin targets on Alzheimer’s disease (AD) and potential causal mechanisms in the brain linking the two. Methods: Genetic proxies for the effects of metformin drug targets were identified as variants in the gene for the corresponding target that associated with HbA 1c level (N=344,182) and expression level of the corresponding gene (N≤31,684). The cognitive outcomes were derived from genome-wide association studies comprising of 527,138 middle-aged Europeans, including 71,880 AD or AD-by-proxy patients. MR estimates representing lifelong metformin use on AD and cognitive function in the general population were generated. Effect of expression level of 22 metformin-related genes in brain cortex (N=6,601 donors) on AD was further estimated. Results: Genetically proxied metformin use equivalent to a 6.75 mmol/mol (1.09%) reduction of HbA 1c was associated with 4% lower odds of AD (odds ratio [OR]=0.964, 95%CI=0.982∼0.946, P=1.06×10 −4 ) in non-diabetic individuals. One metformin target, mitochondrial complex 1 (MCI), showed a robust effect on AD (OR=0.88, P=4.73×10 −4 ) that was independent of AMPK. MR of expression in brain cortex tissue showed that decreased MCI-related gene, NDUFA2 , expression was associated with reduced AD risk (OR=0.95, P=4.64×10 −4 ) and less cognitive decline. Conclusion/interpretation: Metformin use is likely to cause reduced AD risk in the general population. Mitochondrial function and the NDUFA2 gene are likely mechanisms of action in dementia protection. Research in context: What is already known about this subject: Metformin is an anti-diabetic drug with repurposing potential for dementia prevention. In a search of PubMed, Embase and clinicaltrials.gov , a few observational studies suggested the association of metformin use with reduced dementia incidence in diabetic patients What is the key question?: What is the effect of genetically proxied metformin use on Alzheimer’s disease (AD) and cognitive function in the general population, especially for those without diabetes? Is the causal role between the two at least partly influenced by mechanisms in the brain? What are the new findings?: In a Mendelian randomization analysis of over 527,138 individuals (71,880 AD or AD-by-proxy cases), genetically proxied metformin use equivalent to a 6.75 mmol/mol (1.09%) reduction of HbA 1c was associated with 14% lower odds of AD (odds ratio=0.86), where mitochondrial complex I is a key effect modifier. Expression level of a mitochondrial complex I related gene, NDUFA2 , showed an effect on reducing AD risk and less cognitive decline in brain. How might this impact on clinical practice in the foreseeable future?: Our study predicts the efficacy of metformin on reducing AD risk and reducing cognitive decline in the general population, especially for those without diabetes. Mitochondrial function and a mitochondrial related gene, NDUFA2 , could be considered as a novel drug target for dementia prevention. Graphical Tweet Effect of metformin targets reduced 4% of Alzheimer’s disease risk in non-diabetic individuals. @oldz84 @tomgaunt @mendel_random @mrc_ieu